130 related articles for article (PubMed ID: 21517656)
1. Application of comparative effectiveness research in evaluation of treatments for type 2 diabetes mellitus.
Ahmann A
Am J Manag Care; 2011 Mar; 17(2 Suppl):S41-51. PubMed ID: 21517656
[TBL] [Abstract][Full Text] [Related]
2. Decision support tools to optimize economic outcomes for type 2 diabetes.
Shaya FT; Chirikov VV
Am J Manag Care; 2011 Nov; 17 Suppl 14():S377-83. PubMed ID: 22214425
[TBL] [Abstract][Full Text] [Related]
3. Some methodological points to consider when performing systematic reviews in comparative effectiveness research.
Berlin JA; Cepeda MS
Clin Trials; 2012 Feb; 9(1):27-34. PubMed ID: 22049086
[TBL] [Abstract][Full Text] [Related]
4. The intersection of safety and adherence: new incretin-based therapies in patients with type 2 diabetes mellitus.
Zarowitz BJ; Conner C
Pharmacotherapy; 2009 Dec; 29(12 Pt 2):55S-67S. PubMed ID: 19947817
[TBL] [Abstract][Full Text] [Related]
5. How to implement incretin therapy.
Cobble ME
J Fam Pract; 2008 Sep; 57(9 Suppl):S26-31. PubMed ID: 18786341
[TBL] [Abstract][Full Text] [Related]
6. Leveraging observational registries to inform comparative effectiveness research.
Shah BR; Drozda J; Peterson ED
Am Heart J; 2010 Jul; 160(1):8-15. PubMed ID: 20598966
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic approach of type 2 diabetes mellitus with GLP-1 based therapies.
Penfornis A; Borot S; Raccah D
Diabetes Metab; 2008 Feb; 34 Suppl 2():S78-90. PubMed ID: 18640590
[TBL] [Abstract][Full Text] [Related]
8. Pharmacotherapy of hyperglycemia.
Kulasa KM; Henry RR
Expert Opin Pharmacother; 2009 Oct; 10(15):2415-32. PubMed ID: 19743938
[TBL] [Abstract][Full Text] [Related]
9. GLP-1 agonists and dipeptidyl-peptidase IV inhibitors.
Gallwitz B
Handb Exp Pharmacol; 2011; (203):53-74. PubMed ID: 21484567
[TBL] [Abstract][Full Text] [Related]
10. Translating comparative effectiveness into practice: the case of diabetes medications.
Shah ND; Mullan RJ; Breslin M; Yawn BP; Ting HH; Montori VM
Med Care; 2010 Jun; 48(6 Suppl):S153-8. PubMed ID: 20473211
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of incretin-based therapies in patients with type 2 diabetes mellitus.
Gilbert MP; Pratley RE
Eur J Intern Med; 2009 Jul; 20 Suppl 2():S309-18. PubMed ID: 19580950
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of incretin-based therapies in patients with type 2 diabetes mellitus.
Gilbert MP; Pratley RE
Am J Med; 2009 Jun; 122(6 Suppl):S11-24. PubMed ID: 19464424
[TBL] [Abstract][Full Text] [Related]
13. Incretin-based therapies for type 2 diabetes mellitus: properties, functions, and clinical implications.
Nauck MA
Am J Med; 2011 Jan; 124(1 Suppl):S3-18. PubMed ID: 21194578
[TBL] [Abstract][Full Text] [Related]
14. An overview of incretin clinical trials.
Garber AJ; Spann SJ
J Fam Pract; 2008 Sep; 57(9 Suppl):S10-8. PubMed ID: 18786339
[TBL] [Abstract][Full Text] [Related]
15. Diabetes and obesity: therapeutic targeting and risk reduction - a complex interplay.
Niswender K
Diabetes Obes Metab; 2010 Apr; 12(4):267-87. PubMed ID: 20380648
[TBL] [Abstract][Full Text] [Related]
16. The use of patient-reported outcomes (PRO) within comparative effectiveness research: implications for clinical practice and health care policy.
Ahmed S; Berzon RA; Revicki DA; Lenderking WR; Moinpour CM; Basch E; Reeve BB; Wu AW;
Med Care; 2012 Dec; 50(12):1060-70. PubMed ID: 22922434
[TBL] [Abstract][Full Text] [Related]
17. DPP-4 inhibitors and GLP-1 analogues: for whom? Which place for incretins in the management of type 2 diabetic patients?
Halimi S
Diabetes Metab; 2008 Feb; 34 Suppl 2():S91-5. PubMed ID: 18640591
[TBL] [Abstract][Full Text] [Related]
18. The effects of pharmacologic agents for type 2 diabetes mellitus on body weight.
Pi-Sunyer FX
Postgrad Med; 2008 Jul; 120(2):5-17. PubMed ID: 18654064
[TBL] [Abstract][Full Text] [Related]
19. Defining comparative effectiveness research: the importance of getting it right.
Sox HC
Med Care; 2010 Jun; 48(6 Suppl):S7-8. PubMed ID: 20473202
[TBL] [Abstract][Full Text] [Related]
20. Rationale for dipeptidyl peptidase 4 inhibitors: a new class of oral agents for the treatment of type 2 diabetes mellitus.
Campbell RK
Ann Pharmacother; 2007 Jan; 41(1):51-60. PubMed ID: 17190843
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
